Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Tango Therapeutics Inc (TNGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TNGX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 27.93% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 160.68M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 834526 | Beta 0.87 | 52 Weeks Range 1.24 - 12.02 | Updated Date 04/1/2025 |
52 Weeks Range 1.24 - 12.02 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-17 | When Before Market | Estimate -0.3428 | Actual -0.34 |
Profitability
Profit Margin - | Operating Margin (TTM) -993.69% |
Management Effectiveness
Return on Assets (TTM) -25.31% | Return on Equity (TTM) -57.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -74937810 | Price to Sales(TTM) 3.82 |
Enterprise Value -74937810 | Price to Sales(TTM) 3.82 | ||
Enterprise Value to Revenue 14.51 | Enterprise Value to EBITDA -0.91 | Shares Outstanding 108108000 | Shares Floating 46645311 |
Shares Outstanding 108108000 | Shares Floating 46645311 | ||
Percent Insiders 8.4 | Percent Institutions 99.51 |
Analyst Ratings
Rating 4.67 | Target Price 11.5 | Buy 3 | Strong Buy 6 |
Buy 3 | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tango Therapeutics Inc
Company Overview
History and Background
Tango Therapeutics, founded in 2017, is a biotechnology company focused on discovering and developing innovative cancer therapies designed to be more effective and less toxic than traditional treatments. They leverage the principles of synthetic lethality to identify novel drug targets.
Core Business Areas
- Drug Discovery and Development: Focuses on identifying novel cancer targets using synthetic lethality and developing corresponding therapies. This is their primary focus.
- Therapeutic Platforms: Development of platforms to discover and validate new cancer targets. This is a research-driven segment.
- Partnerships and Licensing: Collaborating with other companies to further develop and commercialize their therapeutic candidates.
Leadership and Structure
Tango Therapeutics is led by a management team with experience in drug discovery and development. The organizational structure consists of research, development, clinical, and business operations teams.
Top Products and Market Share
Key Offerings
- TNG908: A MTA-cooperative PRMT5 inhibitor, currently in clinical trials for MTAP-deleted cancers. The competitors are companies developing similar PRMT5 inhibitors. No specific market share data is available, as the product is still in clinical development. Key competitors are companies such as Mirati Therapeutics (MRTX).
- TNG462: A CoREST program inhibitor, currently in Phase 1 clinical trials for patients with specific cancers. The competitors include other pharmaceutical companies developing epigenetic inhibitors. No specific market share data is available, as the product is still in clinical development.
Market Dynamics
Industry Overview
The oncology drug market is a large and rapidly growing market, driven by an aging population and advancements in cancer research. Targeted therapies and immunotherapies are key areas of focus.
Positioning
Tango Therapeutics is positioned as an innovative biotechnology company focused on synthetic lethality. Their competitive advantage lies in their novel target discovery platform.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Tango Therapeutics is positioned to capture a portion of this market through its targeted therapies. The expected total market value is continuously changing, but is estimated to be between $250-$500 billion by 2028. Tango's focus on specific cancer subtypes means their serviceable available market will be smaller, but still significant.
Upturn SWOT Analysis
Strengths
- Novel target discovery platform
- Experienced management team
- Focus on synthetic lethality
- Promising early-stage clinical candidates
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with drug development
- Reliance on successful clinical trial outcomes
- Currently, no products generating revenue
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new drug candidates
- Successful clinical trial results leading to regulatory approvals
- Advancements in cancer diagnostics identifying more patients who could benefit from their therapies
Threats
- Clinical trial failures
- Competition from other biotechnology and pharmaceutical companies
- Changes in regulatory landscape
- Patent challenges
Competitors and Market Share
Key Competitors
- MRTX
- ARRY
- BLUE
Competitive Landscape
Tango Therapeutics competes with other biotechnology and pharmaceutical companies developing cancer therapies. They differentiate themselves through their focus on synthetic lethality and novel target discovery platform. Their competitors are larger, well-established companies with more resources.
Major Acquisitions
BCTG Acquisition Corp.
- Year: 2021
- Acquisition Price (USD millions): 178
- Strategic Rationale: Tango Therapeutics was acquired by BCTG Acquisition Corp. This merger allowed Tango Therapeutics to become a publicly traded company on the Nasdaq.
Growth Trajectory and Initiatives
Historical Growth: Tango Therapeutics has primarily focused on building its research and development pipeline and progressing its lead compounds through preclinical and early clinical development.
Future Projections: Future growth depends on the successful completion of clinical trials and potential regulatory approvals. Analyst estimates vary, but generally project revenue growth if their programs are approved.
Recent Initiatives: Advancing clinical programs for TNG908 and TNG462. Expanding drug discovery efforts to identify new targets and develop new therapies. Securing partnerships to accelerate development and commercialization.
Summary
Tango Therapeutics is a clinical-stage biotechnology company with a focus on novel cancer therapies. Its strengths lie in its innovative platform and early-stage clinical candidates, but it faces challenges due to limited resources and the inherent risks of drug development. Successful clinical trials and strategic partnerships are crucial for its future growth. The financial metrics show a loss with increasing YOY spends. The current cash on hand should be sufficient to fund its research.
Similar Companies
- MRTX
- BLUE
- ARRY
- CRIS
Sources and Disclaimers
Data Sources:
- Company filings (SEC), Investor presentations, Analyst reports, Company Website
Disclaimers:
This analysis is based on available information and is not financial advice. Investing in biotechnology companies involves substantial risk. Market share estimates are rough approximations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tango Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-09-03 | President, CEO & Director Dr. Barbara L. Weber M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 155 | Website https://www.tangotx.com |
Full time employees 155 | Website https://www.tangotx.com | ||
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors; TNG462, which is in Phase 1/2 clinical trial for non- central nervous system cancers including pancreatic and lung cancer; TNG456, a brain-penetrant PRMT5 inhibitor, for central nervous system cancers including glioblastoma; and TNG260, a co-repressor of repressor element-1 silencing transcription (CoREST) inhibitor to reverse the immune evasion effect of STK11 loss-of-function mutations. The company has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.